NCT05984784View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 9, 2023

Primary Completion Date

April 26, 2024

Study Completion Date

April 26, 2024

Conditions
Atopic DermatitisModerate-to-severe Atopic DermatitisAD
Interventions
DRUG

Placebo

Drug: Placebo Intravenous Infusion

DRUG

IMG-007

Drug: IMG-007 Intravenous Infusion

Trial Locations (12)

10128

Markowitz Medical, LLC, New York

19103

Paddington Testing Co, Inc, Philadelphia

32763

Optimal Research Sites, Orange City

33134

Medical Research Center of Miami II Inc, Miami

33612

USF Carol and Frank Morsani Center for Advanced Healthcare, Tampa

48084

Revival Research Institute, LLC, Troy

73170

Central Sooner Research, Oklahoma City

91324

Amicis Research Center, Northridge

91355

Amicis Research Center, Valencia

E3B 1G9

Brunswick Dermatology Center, Fredericton

N6H 5L5

DermEffects, London

G1W4R4

Centre de Recherche Saint-Louis (Québec), Québec

Sponsors

Lead Sponsor

Inmagene LLC
All Listed Sponsors
lead

Inmagene LLC

INDUSTRY

NCT05984784 - A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) | Biotech Hunter | Biotech Hunter